Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study).
about
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy.The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapyGender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda.Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in careComparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE studyDolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.Main partner factors associated with worse adherence to HAART among women in Baltimore, Maryland: a preliminary studyAmbulatory Blood Pressure Monitoring in Individuals with HIV: A Systematic Review and Meta-AnalysisPrevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005.Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.Sex disparities in overall burden of disease among HIV-infected individuals in the Veterans Affairs healthcare systemRace/ethnicity and risk of AIDS and death among HIV-infected patients with access to care.Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities.Liver involvement in human immunodeficiency virus infection.Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda.Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain.Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study.Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.Out of focus: tailoring the cascade of care to the needs of women living with HIV.Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96
P2860
Q33598309-4D1E2E25-2992-4438-AAAD-253671184A7AQ33803909-4631F1B3-EAFB-4E4E-960F-F1D2E73A3B28Q33938797-B05FFD65-1D73-4E34-A962-04F3984A11E6Q34104857-563B1CF3-F7EE-48A1-A852-E644754502B3Q34148055-7560519B-A5D2-498E-A42F-18EC8649139DQ34206123-5090DCE9-20B1-4344-A14C-E7152740C753Q34272202-BE90F1ED-9F63-4C14-8301-C18EABA1B1A3Q34427862-120FB84A-3DB0-4A6D-B03F-02E059E7450DQ34481365-828F4633-C32F-4595-813A-43C66A0550C7Q34823275-DC0D704B-AC9D-4CFA-91DE-8F37AD89234EQ35100296-071BF03C-EF2D-4ECA-8AC5-C4E7AE83BC1EQ35925152-184BF825-7117-4F46-853B-C79AE1C3EA32Q35944787-3CC3D769-B588-4C43-9EE9-6239B8F7B403Q36016153-33881B3D-3E40-44A5-9871-500DC1116E8CQ36294663-267FCDE2-D8CC-47F5-B074-5DC321DF56A1Q36962380-5A9B70AC-F999-455F-8AF7-8DD191E79EA1Q37305191-8715F13F-58EA-41FD-B790-EF89401E120DQ38069146-B985B80A-1F8B-4D61-98F4-B763088357A7Q38852184-6733D9B0-892C-422E-AEB9-6BFF4095F3E2Q38853255-B9DE11D9-A592-4F8D-B9F1-725A070C10CAQ38872693-AE47089B-1DB0-4C54-A436-0D71B1F089F4Q39262818-2BC4AE96-F7C2-4B3F-8655-27CB137B8041Q39372748-79E9F702-E322-4621-854B-7790D37801A4Q39372763-E108841A-EC4A-47A0-ABD5-014244F7E19EQ40062892-2099E52D-8836-45B0-B95D-94EC397DD30BQ58290773-F3CAB85C-99F9-43EA-8CDC-FD3F6589DB2D
P2860
Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Ethnicity, race, and gender. D ...... ts of CPCRA 058 (FIRST Study).
@en
Ethnicity, race, and gender. D ...... ts of CPCRA 058 (FIRST Study).
@nl
type
label
Ethnicity, race, and gender. D ...... ts of CPCRA 058 (FIRST Study).
@en
Ethnicity, race, and gender. D ...... ts of CPCRA 058 (FIRST Study).
@nl
prefLabel
Ethnicity, race, and gender. D ...... ts of CPCRA 058 (FIRST Study).
@en
Ethnicity, race, and gender. D ...... ts of CPCRA 058 (FIRST Study).
@nl
P2093
P1476
Ethnicity, race, and gender. D ...... ts of CPCRA 058 (FIRST Study).
@en
P2093
Avis J Thomas
Ellen M Tedaldi
Judith Absalon
Judith C Shlay
Mary van den Berg-Wolf
P304
P356
10.1097/QAI.0B013E3181609DA8
P407
P577
2008-04-01T00:00:00Z